Lucas Buchheim-Jurisson

Lucas Buchheim-Jurisson is an accomplished business development professional with a strong background in the biotechnology and technology sectors. Currently serving as the Associate Director of Business Development for Gene Therapy & Gene Editing at Ginkgo Bioworks, Inc. since April 2024, Lucas is also an investor at Ochre Bio. Previously, tenure at Excision BioTherapeutics included roles as Director of Business Development & Strategy, Associate Director of Corporate Strategy, and Chief of Staff, contributing to the development of cutting-edge CRISPR-based therapies. Additional experience includes a position as Business Development & Product Strategy Associate at Rigetti Computing, focused on quantum computing technologies, and as an Enterprise Services Associate at Quid, a natural language processing company. Lucas began the career with a summer analyst position at J.P. Morgan and holds a Bachelor's Degree in Political Science from the University of Chicago.